Elekta Secures €100M Debt Financing from European Investment Bank

Elekta, a Stockholm-based medical technology company, has raised €100 million in debt financing from the European Investment Bank (EIB). The funding, dated August 31, 2026, is intended to support the company's ongoing development of precision radiation medicine solutions.

Company Overview

Founded in 1972 and listed on Nasdaq Stockholm, Elekta specializes in radiotherapy, radiosurgery, and brachytherapy systems, along with the software used to plan and deliver treatment. Its technologies are employed to treat various cancers, including brain, breast, lung, kidney, pancreatic, and prostate tumors, as well as neurological conditions such as essential tremor and certain forms of epilepsy. The company's solutions reach more than 2 million patients annually across over 120 countries.

With approximately 4,000 employees and operations in more than 40 nations, Elekta is a significant player in the global medical technology sector.

Funding Details

The €100 million debt facility from the EIB represents a substantial financial boost for the company. While the specific purpose of the funding has not been disclosed, it is likely to be directed toward research and development, innovation, and potentially expanding access to its technologies worldwide.

Strategic Importance

This financing aligns with Elekta's mission to improve patient outcomes through advanced radiation therapy. The support from the EIB, a long-term partner in European infrastructure and innovation projects, underscores the strategic importance of Elekta's work in the healthcare sector.

As Elekta continues to innovate in the field of precision medicine, this capital injection will help ensure that it remains at the forefront of cancer treatment technology. Further details on how the funds will be utilized are expected to be announced in due course.